NextCure (NXTC) Operating Income (2018 - 2026)
NextCure (NXTC) posted quarterly Operating Income of -$10.1 million for Q1 2026, up 13.05% year-over-year from -$8.9 million in Q1 2025, and down 3.57% quarter-over-quarter from -$9.8 million in Q4 2025.
NextCure (NXTC) Operating Income (2018 - 2026) Analysis & Trends
NextCure's Operating Income history runs 9 years deep, the most recent figure standing at -$10.1 million for Q1 2026.
- In Q1 2026, Operating Income rose 13.05% year-over-year to -$10.1 million; the TTM figure through Mar 2026 stood at -$56.1 million (down 5.72% YoY), while the FY2025 annual figure was -$57.6 million, up 3.57% from the prior year.
- Operating Income for Q1 2026 stood at -$10.1 million, down from -$9.8 million in the prior quarter.
- The five-year high for Operating Income was -$8.9 million in Q3 2025, with the low at -$27.3 million in Q2 2025.
- The 5-year median for Operating Income is -$16.5 million (2024), against an average of -$15.9 million.
- Peak annual rise in Operating Income reached 36.51% in 2025, while the deepest fall reached 65.47% in 2025.
- NextCure's Operating Income stood at -$17.8 million in 2022, then advanced by 11.15% to -$15.8 million in 2023, then climbed by 21.12% to -$12.5 million in 2024, then rose by 21.66% to -$9.8 million in 2025, then slipped by 3.57% to -$10.1 million in 2026.
- Business Quant data shows NXTC's Operating Income at -$10.1 million in Q1 2026, -$9.8 million in Q4 2025, and -$8.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | -15.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.09 Mn |
| Mar 31, 2026 | -10.11 Mn |
| Dec 31, 2025 | -9.76 Mn |
| Sep 30, 2025 | -8.95 Mn |
| Jun 30, 2025 | -27.29 Mn |
| Mar 31, 2025 | -11.62 Mn |
| Dec 31, 2024 | -12.46 Mn |
| Sep 30, 2024 | -12.50 Mn |
| Jun 30, 2024 | -16.49 Mn |
| Mar 31, 2024 | -18.30 Mn |
| Dec 31, 2023 | -15.79 Mn |
| Sep 30, 2023 | -15.62 Mn |
| Jun 30, 2023 | -19.16 Mn |
| Mar 31, 2023 | -17.07 Mn |
| Dec 31, 2022 | -17.77 Mn |
| Sep 30, 2022 | -19.24 Mn |
| Jun 30, 2022 | -18.13 Mn |
| Mar 31, 2022 | -20.77 Mn |
| Dec 31, 2021 | -17.07 Mn |
| Sep 30, 2021 | -18.51 Mn |